A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

November 29, 2023

Study Completion Date

November 29, 2023

Conditions

Neurodegenerative DiseasesAlzheimer's Disease

Interventions

DRUG

SNP318 (A)

Capsule for oral administration

DRUG

Placebo (B)

Placebo capsules matching the SNP318 capsules

Trial Locations (1)

CMAX Clinical Research, Adelaide

All Listed Sponsors

lead

SciNeuro

INDUSTRY